Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 1689 | 3p21.1 | PBRM1 | polybromo 1 | |
Mouse | - | 1704 | 14 B | Pbrm1 | polybromo 1 | |
Rat | - | - | 16p16 | Pbrm1 | polybromo 1 |
Previous and Unofficial Names |
BAF180 | PB1 |
Database Links | |
Alphafold | Q86U86 (Hs) |
CATH/Gene3D | 1.10.30.10, 1.20.920.10 |
ChEMBL Target | CHEMBL1795184 (Hs) |
Ensembl Gene | ENSG00000163939 (Hs), ENSMUSG00000042323 (Mm), ENSRNOG00000028227 (Rn) |
Entrez Gene | 55193 (Hs), 66923 (Mm), 306254 (Rn) |
Human Protein Atlas | ENSG00000163939 (Hs) |
KEGG Gene | hsa:55193 (Hs), mmu:66923 (Mm), rno:306254 (Rn) |
OMIM | 606083 (Hs) |
Pharos | Q86U86 (Hs) |
RefSeq Nucleotide | NM_018313 (Hs), NM_001081251 (Mm) |
RefSeq Protein | NP_060783 (Hs), NP_001074720 (Mm) |
UniProtKB | Q86U86 (Hs) |
Wikipedia | PBRM1 (Hs) |
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
We have included PBRM1 in GtoImmuPdb as its repression has been reported to re-sensitise tumour cells with acquired resistance to immunotherapy (e.g. checkpoint blockade by anti-PD-1 or anti-CTLA-4 mAbs) to T cell-mediated attack [4]. |
General Comments |
PBRM1 is a component of the SWI/SNF chromatin remodeling PBAF complex. More than one fifth of human cancers carry mutations in PBAF subunit genes. The PBAF complex is reported to confer tumour cell resistance to T cell-mediated killing [3], suggesting molecular targets for the development of novel interventions to treat cancers driven by perturbed mSWI/SNF activity [7]. PBRM1 has specifically been identified as a potential target for renal cell carcinoma [1,5]. |
1. Brugarolas J. (2013) PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J, 19 (4): 324-32. [PMID:23867514]
2. Cochran AG, Flynn M. (2023) GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1. J Med Chem, 66 (18): 13116-13134. [PMID:37702400]
3. Kadoch C, Crabtree GR. (2015) Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv, 1 (5): e1500447. [PMID:26601204]
4. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P et al.. (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science, 359 (6377): 770-775. [PMID:29301958]
5. Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M et al.. (2015) BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn, 15 (9): 1201-10. [PMID:26166446]
6. SGC. PFI-3 A Selective chemical probe for SMARCA bromodomains. Accessed on 10/11/2014. Modified on 04/08/2023. thesgc.org, https://www.thesgc.org/chemical-probes/PFI-3
7. St Pierre R, Kadoch C. (2017) Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr Opin Genet Dev, 42: 56-67. [PMID:28391084]
8. Taylor AM, Bailey C, Belmont LD, Campbell R, Cantone N, Côté A, Crawford TD, Cummings R, DeMent K, Duplessis M et al.. (2022) GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1. J Med Chem, 65 (16): 11177-11186. [PMID:35930799]
Non-enzymatic BRD containing proteins: polybromo 1. Last modified on 18/01/2024. Accessed on 19/09/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2738.